Differences between squamous cell carcinoma and adenocarcinoma of the lung: are adenocarcinoma and squamous cell carcinoma prognostically equal? 2012

Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
Division of Thoracic Surgery, National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Chiba, Japan.

OBJECTIVE We analyzed pulmonary squamous cell carcinoma and adenocarcinoma patient survival in our single institution database, to evaluate the relationship of histologic analysis to survival and tumor aggressiveness. METHODS We reviewed 1856 consecutive patients with surgically resected pulmonary squamous cell carcinoma or adenocarcinoma regarding their clinicopathologic characteristics, overall survival and recurrence-free proportion. RESULTS In squamous cell carcinoma patients, there were more elderly male smokers and more patients with T2-4 tumors, moderately/poorly differentiated tumors, lymph node metastasis or vascular invasion than in adenocarcinoma patients. In all patients and in pN0 patients, patients with squamous cell carcinoma showed significantly poorer overall survival than those with adenocarcinoma, but there were no statistically significant differences in the recurrence-free proportion between the two histologic types. There were statistically significantly more lung cancer-specific deaths in patients with adenocarcinoma than in patients with squamous cell carcinoma (P= 0.001). CONCLUSIONS There were no differences in the development of recurrence between squamous cell carcinoma and adenocarcinoma of the lung, but considerable differences in overall survival were observed between the two histologic types. According to the stage grouping strategy of the TNM Classification for Lung and Pleural Tumours, these two histologic types need to be staged differently. This survival difference, however, may reflect the difference in patient background rather than in biologic aggressiveness between the two histologic types.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
November 2002, American journal of clinical pathology,
Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
January 2005, World journal of surgery,
Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
October 2014, Anticancer research,
Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
April 2024, Japanese journal of clinical oncology,
Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
January 2024, Frontiers in oncology,
Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
December 2013, Lung cancer (Amsterdam, Netherlands),
Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
April 2017, Oncotarget,
Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
July 2020, Journal of computational biology : a journal of computational molecular cell biology,
Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
December 1980, Gynecologic oncology,
Akikazu Kawase, and Junji Yoshida, and Genichiro Ishii, and Masayuki Nakao, and Keiju Aokage, and Tomoyuki Hishida, and Mitsuyo Nishimura, and Kanji Nagai
April 2019, Journal of cellular physiology,
Copied contents to your clipboard!